ACETO Subsidiary, Rising Pharmaceuticals, Launches Atenolol Tablets, 25mg, 50mg and 100mg
Adicet Bio, Inc. (ACET)
Last adicet bio, inc. earnings: 5/3 05:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
aceto.com/ir/index.html
Company Research
Source: GlobeNewswire
PORT WASHINGTON, N.Y., Feb. 07, 2018 (GLOBE NEWSWIRE) -- ACETO Corporation (NASDAQ:ACET), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, its finished dosage form generics subsidiary, has launched Atenolol Tablets, 25mg, 50mg and 100mg, an FDA-approved generic version of the reference listed drug, TENORMIN® from Alvogen Malta Operations LTD, which is indicated for hypertension. Atenolol is currently listed on the FDA Drug Shortages database. The Atenolol Tablets, 25mg, 50mg and 100mg, had sales of approximately $60.9 million for the 12 months ending December 2017, according to IMS Health. ACETO Corporation sells generic prescription products and over-the-counter pharmaceutical products under its Rising label to leading wholesalers, chain drug stores, distributors and mass merchandisers, and the launch of the Atenolol
Show less
Read more
Impact Snapshot
Event Time:
ACET
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACET alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACET alerts
High impacting Adicet Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ACET
News
- Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual ConferenceBusiness Wire
- Adicet Bio, Inc. (NASDAQ: ACET) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]Yahoo! Finance
- Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Adicet Bio (ACET) Loses -16.39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner [Yahoo! Finance]Yahoo! Finance
ACET
Earnings
- 3/19/24 - Beat
ACET
Sec Filings
- 4/12/24 - Form PRE
- 3/22/24 - Form 8-K
- 3/22/24 - Form 424B5
- ACET's page on the SEC website